Supplemental Table 1. Cohort origins and demographics*

	Discovery Cohort			Replication Cohort												
	F	M	Total	Germany			Texas		Delaware		UK			Utah		Total
				F	M	Unk	F	M	F	M	F	M	Unk	F	M	
Oligo-articular	370 (80.3%)	91 (19.7%)	461	280 (76.1%)	88 (23.9%)	21	60 (87.0%)	9 (13.0%)	15 (88.2%)	2 (11.8%)	352 (71.3%)	142 (28.7%)	17	131 (69.3%)	58 (30.7%)	1175
Poly RFneg	277 (78.5%)	76 (21.5%)	353	93 (66.9%)	46 (33.1%)	3	63 (80.7%)	15 (19.2%)	7 (100%)	0 (0%)	188 (79.3%)	49 (20.7%)	7	78 (79.6%)	20 (20.4%)	569
Total Cases	647 (79.5%)	167 (20.5%)	814	373 (73.6%)	134 (26.4%)	24	123 (83.7%)	24 (16.3%)	22 (91.7%)	2 (8.3%)	540 (73.9%)	191 (26.1%)	24	209 (72.8%)	78 (27.1%)	1744
Local Controls	336 (55.6%)	322 (48.9%)	658	237 (47.6%)	261 (52.4%)	2	178 (65.0%)	96 (35.0%)			2647 (48.2%)	2733 (50.8%)		511 (59.7%)	345 (40.3%)	7010
nonGAIN Controls	986 (41.1%)	1414 (58.9%)	2400													

*M = male; F = female; Unk=unknown; Poly RFneg = Rheumatoid Factor negative Polyarticular JIA; For the UK cohort, the controls are from Wellcome Trust Case-Control Consortium, For the Discovery cohort the out-of-study controls include Molecular Genetics of Schizophrenia non-GAIN Samples.